2023年7月22日

全國公認的股東權利律師事務所,正在調查潛在索賠Waldencast Plc(納斯達克:瓦爾德),Relmada療法,Inc .(納斯達克:RLMD) DoubleVerify控股有限公司(NYSE: DV),城堡和生物科學公司(納斯達克:CSTL)。我們調查的擔憂這些公司是否有違反了聯邦證券法律和/或從事其他非法商業行為。關於每種情況下的額外信息可以找到鏈接。Waldencast Plc(納斯達克:瓦爾德)4月25日,2023年,Waldencast宣布它將無法按時提交2022年度報告,將推遲其2022財年第四季度財報電話會議由於持續審查公司的2022年年終財務報表。具體地說,該公司正在進行一個關於某些會計問題分析與某些Obagi產品在越南市場的銷售。在這個新聞,Waldencast股票的價格下降了0.57美元每股,或約6.20%,從9.20美元,收於每股8.63美元4月25日,2023年。有關Waldencast調查去的更多信息:https://bespc.com/cases/WALD Relmada療法,Inc .(納斯達克:RLMD)在10月13日開盤之前,2022年,Relmada宣布第三的依賴研究的結果(rel - 1017 - 303),評估藥物rel - 1017作為單藥治療重度抑鬱症(MDD)。Relmada透露,第三依賴試驗沒有實現其主要終點,這是一個顯著的改善抑鬱症狀與安慰劑相比28天,作為衡量Mongomery-Asberg抑鬱量表(MADRS)。具體來說,rel - 1017治療顯示減少MADRS 28天的14.8點和13.9點安慰劑,高於預期的安慰劑的反應。Relmada描述,“[p] aradoxical結果中觀察到的某些研究網站,在安慰劑顯著優於rel - 1017。“這個消息後,Relmada股價下跌近80%,收於每股6.48美元10月13日,2022年。 For more information on the Relmada investigation go to: https://bespc.com/cases/RLMD DoubleVerify Holdings, Inc. (NYSE: DV) On May 2, 2023, Spruce Point Capital Management published a report alleging that there is evidence DoubleVerify engaged in manipulative and deceptive financial reporting related to its international business. On this news, DoubleVerify’s share price fell $1.69, or 5.8%, to close at $27.22 per share on May 2, 2023, thereby injuring investors. For more information on the DoubleVerify investigation go to: https://bespc.com/cases/DV Castle Biosciences, Inc. (NASDAQ: CSTL) Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental health conditions. On June 2, 2023, during the 2023 American Society of Clinical Oncology annual meeting, Castle Biosciences discussed trial results for its IDgenetix tests, which diagnoses moderate to severe depression. On this news, the price of Castle shares declined by $11.07 per share, or approximately 48.70%, from $22.73 per share to close at $11.66 on June 5, 2023. For more information on the Castle investigation go to: https://bespc.com/cases/CSTL About Bragar Eagel & Squire, P.C. : Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: